Fullerene-porphyrin nanostructures in photodynamic therapy

Nanomedicine

Volumn 5, Issue 2, 2010, Pages 307-317

  Constantin, Carolina ^a   Neagu, Monica ^a   Ion, Rodica Mariana ^b,c   Gherghiceanu, Mihaela ^a   Stavaru, Crina ^d  

^a VICTOR BABES NATIONAL INSTITUTE OF PATHOLOGY   (Romania)

^b NATIONAL RESEARCH AND DEVELOPMENT INSTITUTE FOR CHEMISTRY AND PETROCHEMISTRY ICECHIM   (Romania)

^c VALAHIA UNIVERSITY OF TARGOVISTE   (Romania)

^d CANTACUZINO INSTITUTE   (Romania)

Author keywords

Fullerene porphyrin; Nanostructures; Photodynamic therapy; Reactive oxygen species

Indexed keywords

CARBON NANOTUBE; FULLERENE; MACROGOL; NANOMATERIAL; PACLITAXEL; PHOTOSENSITIZING AGENT; PORPHYRIN; POVIDONE; SINGLET OXYGEN; TETRAPHENYLPORPHYRIN;

CANCER THERAPY; CHEMICAL STRUCTURE; DERIVATIZATION; HUMAN; NONHUMAN; PHOTODYNAMIC THERAPY; PRECANCER; PRIORITY JOURNAL; REVIEW; TUMOR CELL;

ANIMALS; ANOXIA; FULLERENES; HUMANS; K562 CELLS; MICE; MICROSCOPY, ELECTRON, TRANSMISSION; NANOMEDICINE; NANOSTRUCTURES; NANOTECHNOLOGY; OXYGEN; PHOTOCHEMISTRY; PHOTOCHEMOTHERAPY; PHOTOSENSITIZING AGENTS; PORPHYRINS;

EID: 77952482204     PISSN: 17435889     EISSN: None     Source Type: Journal    
DOI: 10.2217/nnm.09.111     Document Type: Review

References (73)

1. Gust D, Moore TA, Moore AL: Mimicking bacterial photosynthesis. Pure Appl. Chem. 70, 2189-2200 (1998).
2. Liddell PA, Kuciauskas D, Sumida JP et al.: Photoinduced charge separation and charge recombination to a triplet state in a carotene-porphyrin- fullerene triad. J. Am. Chem. Soc. 119, 1400-1405 (1997).
3. Imahori H, Hagiwara K, Aoki M et al.: Linkage and solvent dependence of photoinduced electron transfer in zincporphyrin-C60 dyads. J. Am. Chem. Soc. 118, 11771-11782 (1996).
4. Nyst HJ, Tan IB, Stewart FA, Balm AJ: Is photodynamic therapy a good alternative to surgery and radiotherapy in the treatment of head and neck cancer? Photodiagnosis Photodyn. Ther. 6(1), 3-11 (2009).
5. Tierney E, Barker A, Ahdout J, Hanke C W, Moy RL, Kouba DJ: Photodynamic therapy for the treatment of cutaneous neoplasia, infammatory disorders, and photoaging. Dermatol. Surg. 35(5), 725-746 (2009).
6. Ascencio M, Collinet P, Cosson M, Vinatier D, Mordon S: The place of photodynamic therapy in gynecology. Gynecol. Obstet. Fertil. 35(11), 1155-1165, 2007
7. Ortiz-Policarpio B, Lui H: Methyl aminolevulinate-PDT for actinic keratoses and superfcial nonmelanoma skin cancers. Skin Therapy Lett. 14(6), 1-3 (2009).
8. Ion R-M, Boda D: Porphyrin-based supramolecular nanotubes generated by aggregation processes. Rev. Chim. Bucharest 59(2), 205-207 (2008).
9. Boda D, Neagu M, Constantin C, Diaconeasa A, Ianosi S, Ion RM: New photosensitizers vs ALA in experimental PDT of Actinic Keratosis-a case report. Anal. St. Univ Alex I.Cuza, Seria Genetica si Biologie Moleculara, Iasi. TOM X(3), 61-69 (2009).
10. Moore CM, Pendse D, Emberton M: Photodynamic therapy for prostate cancer-a review of current status and future promise. Nat. Clin. Pract. Urol. 6(1), 18-30, (2009).
11. US Department Of Health And Human Services; Food And Drug Administration Center For Drug Evaluation And Research; Offce Of Pharmaceutical Science. Offce Of Generic Drugs: Approved Drug Products With Therapeutic Equivalence Evaluations. (29th Edition). 3-1, 3-24 (2009).
12. Awan MA, Tarin SA: Review of photodynamic therapy. Surgeon 4(4), 231-236 (2006).
13. Brown SB, Brown EA, Walker I: The present and future role of photodynamic therapy in cancer treatment. Lancet Oncol. 5(8), 497-508 (2004).
14. Palumbo G: Photodynamic therapy and cancer: a brief sightseeing tour. Expert Opin. Drug Deliv. 4(2), 131-148 (2007).
15. Juzenas P, Chen W, Sun Y-P et al.: Quantum dots and nanoparticles for photodynamic and radiation therapies of cancer. Adv. Drug Deliv. Rev. 60, 1600-1614 (2008).
16. Mroz P, Tegos GP, Gali H, Wharton T, Sarna T, Hamblin MR: Photodynamic therapy with fullerenes. Photochem. Photobiol. Sci. 6, 1139-1149 (2007).
17. Taylor R, Burley GA: Production, isolation and purifcation of fullerenes. In: Fullerenes: Principles and Applications. Langa F, Nierengarten J-F (Eds). Society of Chemistry (2007).
18. Rudalevige T, Francis AH, Zand R: Spectroscopic studies of fullerene aggregates. J. Phys. Chem. 102, 9797-9802 (1998).
19. Mroz P, Pawlak A, Satti M et al.: Functionalized fullerenes mediate photodynamic killing of cancer cells: type I versus type II photochemical mechanism. Free Radic. Biol. Med. 43(5), 711-719 (2007).
20. Jain KK: Role of nanobiotechnology in the development of nanomedicine. In: Nanoparticulate Drug Delivery Systems. Thassu D, Deleers M, Pathak Y (Eds). 173-183 (2007).
21. Wilson SR: Nanomedicine: fullerene and carbon nanotube biology. In: Perspectives in Fullerene Nanotechnology. Osawa E (Ed.). Kluwer Academic Publishers (2002).
22. Zuin S, Pojana G, Marcomini A: Effect-oriented physicochemical characterization of nanomaterials. In: Nanotoxicology, Characterization, Dosing and Health Effects. Monteiro-Riviere NA, Lang Tran C (Eds). Taylor & Francis, NY, USA 3 (2007).
23. Brant J, Lecoanet H, Hotze M, Wiesner M: Comparison of electrokinetic properties of colloidal fullerenes (n-C60) formed using two procedures. Environ. Sci. Technol. 39, 6343-6351 (2005).
24. Masala O, Seshadri R: Synthesis routes for large volumes of nanoparticles. Annu. Rev. Mater. Res. 34, 41-81 (2004).
25. Brayner R, Ferrari-Iliou R, Brivois N, Djediat S, Benedetti MF, Fiévet F: Toxicological impact studies based on Escherichia coli bacteria in ultrafne ZnO nanoparticles colloidal medium. Nano Lett. 6, 866-870 (2006).
26. Neagu M, Manda G, Constantin C, Radu E, Ion R-M: Synthetic porphyrins in experimental photodynamic therapy induce different antitumoral effect. J. Porphyr. Phthalocyanines 11(1), 58-65 (2007).
27. Smith KM: General features of the structure and chemistry of porphyrin compounds. In: Porphyrins and Metalloporphyrins. Elsevier, Amsterdam, The Netherlands 20-27 (1975).
28. Ostrowski S, Mikus A: A new approach to the synthesis of porphyrin-fullerene dyads. Mol. Divers. 6, 315-321 (2003).
29. Langa F, De la Cruz P: Basic principles of the chemical reactivity of fullerens. In: Fullerenes: Principles and Applications. Fernando Langa F, Nierengarten J-F (Eds). Royal Society of Chemistry, London, UK 16 (2007).
30. Krokosz A: Fullerenes in biology. Postepy Biochem. 53(1), 91-96 (2007).
31. Maisch T: A new strategy to destroy antibiotic resistant microorganisms: antimicrobial photodynamic treatment. Mini Rev. Med. Chem. 9(8), 947-983 (2009).
32. Markovic Z, Trajkovic V: Biomedical potential of the reactive oxygen species generation and quenching by fullerenes (C60). Biomaterials 29(26), 3561-3573 (2008).
33. Nayak CS: Photodynamic therapy in dermatology. Indian J. Dermatol. Venereol. Leprol. 71(3), 155-160 (2005).
34. Hartnagel U, Balbinot D, Jux N, Hirsch A: Electrophoresis of electrostatically assembled fullerene-porphyrin conjugates. Org. Biomol. Chem. 4(9), 1785-1795 (2006).
35. Tong LH, Wietor JL, Clegg W, Raithby PR, Pascu SI, Sanders JK: Supramolecular assemblies of tripodal porphyrin hosts and C60. Chemistry 14(10), 3035-3044 (2008).
36. Milanesio ME, Alvarez MG, Rivarola V, Silber JJ, Durantini EN: Porphyrin-fullerene C60 dyads with high ability to form photoinduced charge-separated state as novel sensitizers for photodynamic therapy. Photochem. Photobiol. 81(4), 891-897 (2005).
37. Benyamini H, Shulman-Peleg A, Wolfson HJ, Belgorodsky B, Fadeev L, Gozin M: Interaction of c(60)-fullerene and carboxyfullerene with proteins: docking and binding site alignment. Bioconjug. Chem. 17(2), 378-386 (2006).
38. Belgorodsky B, Fadeev L, Kolsenik J, Gozin M: Biodelivery of a fullerene derivative. Bioconjug. Chem. 18(4), 1095-1100 (2007).
39. Doi Y, Ikeda A, Akiyama M et al.: Intracellular uptake and photodynamic activity of water-soluble [60]-and [70] fullerenes incorporated in liposomes. Chemistry 14(29), 8892-8897 (2008).
40. Ikeda A, Nagano M, Akiyama M et al.: Photodynamic activity of C70 caged within surface-cross-linked liposomes. Chem. Asian J. 4(1), 199-205 (2009).
41. Verma S, Watt GM, Mai Z, Hasan T: Strategies for enhanced photodynamic therapy effects. Photochem. Photobiol. 83(5), 996-1005 (2007).
42. Boyd PD, Reed CA: Fullerene-porphyrin constructs. Acc. Chem. Res. 38(4), 235-242 (2005).
43. Alvarez MG, Prucca C, Milanesio ME, Durantini EN, Rivarola V: Photodynamic activity of a new sensitizer derived from porphyrin-C60 dyad and its biological consequences in a human carcinoma cell line. Int. J. Biochem. Cell Biol. 38(12), 2092-2101 (2006).
44. Chandra R, Tiwari M, Kaur P, Sharma M, Jain R, Dass S: Metalloporphyrins-applications and clinical signifcance. Indian J. Clin. Biochem. 15(Suppl.), 183-199 (2000).
45. Hotze EM, Labille J, Alvarez P, Wiesner MR: Mechanisms of photochemistry and reactive oxygen production by fullerene suspensions in water. Environ. Sci. Technol. 42(11), 4175-4180 (2008).
46. Pickering KD, Wiesner MR: Fullerol-sensitized production of reactive oxygen species in aqueous solution. Environ. Sci. Technol. 39, 1359-1365 (2005).
47. Oberdorster G, Maynard A, Donaldson K et al.; ILSI Research Foundation/Risk Science Institute Nanomaterial Toxicity Screening Working Group: Principles for characterizing the potential human health effects from exposure to nanomaterials: elements of a screening strategy. Part Fibre Toxicol. 2, 1-35 (2005).
48. Wallace WE, Keane MJ, Murray DK, Chisholm WP, Maynard AD, Ong T: Phospholipid lung surfactant and nanoparticle surface toxicity: lessons from diesel soots and silicate dusts. J. Nanoparticle Res. 9, 23-38 (2007).
49. Yamashita K, Sakai M, Takemoto N et al.: Attenuation of delayed-type hypersensitivity by fullerene treatment. Toxicology 261(1-2), 19-24 (2009).
50. VanHandel M, Alizadeh D, Zhang L et al.: Selective uptake of multi-walled carbon nanotubes by tumor macrophages in a murine glioma model. J. Neuroimmunol. 208(1-2), 3-9 (2009).
51. Liu Z, Chen K, Davis C, Sherlock S, Cao Q, Chen X, Dai H: Drug delivery with carbon nanotubes for in vivo cancer treatment. Cancer Res. 68(16), 6652-6660 (2008).
52. Usenko CY, Harper SL, Tanguay RL: In vivo evaluation of carbon fullerene toxicity using embryonic zebrafsh. Carbon 45(9), 1891-1898 (2007).
53. Bystrzejewska-Piotrowska G, Golimowski J, Urban PL: Nanoparticles: their potential toxicity, waste and environmental management. Waste Manag. 29(9), 2587-2595 (2009).
54. Markovic Z, Trajkovic V: Biomedical potential of the reactive oxygen species generation and quenching by fullerenes (C60). Biomaterials 29(26), 3561-3573 (2008).
55. Kolosnjaj J, Szwarc H, Moussa F: Toxicity studies of fullerenes and derivatives. Adv. Exp. Med. Biol. 620, 168-180 (2007).
56. Webster TJ, Ahn ES: Nanostructured biomaterials for tissue engineering bone. Adv. Biochem. Eng. Biotechnol. 103, 275-308 (2007).
57. Balani K, Anderson R, Laha T et al.: Plasma-sprayed carbon nanotube reinforced hydroxyapatite coatings and their interaction with human osteoblasts in vitro. Biomaterials 28, 618-624 (2007).
58. Zhao B, Hu H, Mandal SK, Haddon RC: A bone mimic based on the self-assembly of hydroxyapatite on chemically functionalized single-walled carbon nanotubes. Chem. Mater. 17, 3235-3241 (2005).
59. Hu H, Ni Y, Montana V, Haddon RC, Parpura V: Chemically functionalized carbon nanotubes as substrates for neuronal growth. Nano Lett. 4, 507-511 (2004).
60. Ni Y, Hu H, Malarkey EB et al.: Chemically functionalized water soluble single-walled carbon nanotubes modulate neurite outgrowth. J. Nanosci. Nanotechnol. 5, 1707-1712 (2005).
61. Wang X, Wang Y, Chen ZG, Shin DM: Advances of cancer therapy by nanotechnology. Cancer Res. Treat. 41(1), 1-11 (2009).
62. Singh R, Lillard JW Jr: Nanoparticle-based targeted drug delivery. Exp. Mol. Pathol. 86(3), 215-223 (2009).
63. Jiang W, Kim BY, Rutka JT, Chan WC: Advances and challenges of nanotechnology-based drug delivery systems. Expert Opin. Drug Deliv. 4(6), 621-633 (2007).
64. Kaiser J-P, Krug HF, Wick P: Nanomaterial cell interactions: how do carbon nanotubes affect cell physiology? Nanomedicine 4(1), 57-63 (2008).
65. Kulamarva A, Raja PM, Bhathena J et al.: Microcapsule carbon nanotube devices for therapeutic applications. Nanotechnology 20(2), 25612 (2009).
66. 2+-magnetic isotope effect. Eur. J. Med. Chem. 44(4), 1554-1569 (2009).
67. He J, Liu G, Gupta S, Zhang Y, Rusckowski M, Hnatowich DJ: Amplifcation targeting: a modifed pretargeting approach with potential for signal amplifcation-proof of a concept. J. Nucl. Med. 45(6), 1087-1095 (2004).
68. Bolskar RD: Gadofullerene MRI contrast agents. Nanomed. 3(2), 201-213 (2008).
69. Mody V V, Nounou MI, Bikram M: Novel nanomedicine-based MRI contrast agents for gynecological malignancies. Adv. Drug Deliv. Rev. 61, 795-807 (2009).
70. Debbage P: Targeted drugs and nanomedicine: present and future. Curr. Pharm. Des. 15(2), 153-172 (2009).
71. Ferreira L: Nanoparticles as tools to study and control stem cells. J. Cell Biochem. 108(4), 746-752 (2009).
72. Del Vecchio S, Zannetti A, Fonti R, Pace L, Salvatore M: Nuclear imaging in cancer theranostics. Q. J. Nucl. Med. Mol. Imaging 51(2), 152-163 (2007).
73. Debbage P, Jaschke W: Molecular imaging with nanoparticles: giant roles for dwarf actors. Histochem, Cell Biol. 130(5), 845-875 (2008).